Prediction of efficacy in isolated fresh tissues

Prediction of efficacy in isolated fresh tissues

Biopta’s human tissue models provide an excellent first look at how your test compound will perform far in advance of being in the clinic.

Our models can provide invaluable human efficacy data while your compounds are still in pre-clinical development; greatly increasing the predictability of your drug development, meaning ‘go’ or ‘no-go’ decisions can be made with confidence prior to expensive clinical studies.

Both healthy and diseased tissues are often freely available and enable researchers to make detailed ‘phase 0’ comparisons in select patient populations without the associated large costs. Human efficacy data adds significant value for investors and can be extremely useful when looking for expected secondary applications or repositioning of current compounds.

Biopta offers a range of validated assays across all therapeutic areas as well as a dedicated assay development team who are able to provide customised assays to meet your specific needs.The flow chart below shows a typical project at Biopta- note that the tissue type and endpoint is highly flexible, here, an example is shown using small blood vessels dissected from subcutaneous adipose tissues.


Efficacy data in living human tissues is a powerful method to demonstrate the value of your compounds:

- For investors- confidence increased by early demonstration of human efficacy in the target patient group

- Adds commercial value- reduces risk of phase II failure, which adds early stage value to the compounds

- De-risks development by selecting compounds with demonstrable human efficacy


Contact Biopta today to design a protocol that will demonstrate the efficacy of your compounds in human fresh tissues.

Live chat by BoldChat